查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938432

過敏和免疫學市場 - 全球產業規模、佔有率、趨勢、機會和預測（按治療類型、過敏類型、分銷管道、地區和競爭格局分類，2021-2031年）

Allergy And Immunology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Allergy Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球過敏和免疫學市場預計將從 2025 年的 28.1 億美元成長到 2031 年的 39.6 億美元，複合年成長率為 5.88%。

該領域包括診斷工具、免疫療法和藥物干預，旨在治療氣喘、過敏、自體免疫疾病等免疫系統疾病。成長的主要促進因素是全球範圍內過敏性疾病的增加（由於都市化和環境污染）、醫療保健成本的上升以及人們對免疫健康的日益重視。

市場概覽
預測期 2027-2031
市場規模：2025年 28.1億美元
市場規模：2031年 39.6億美元
複合年成長率：2026-2031年 5.88%
成長最快的細分市場 醫院藥房
最大的市場 北美洲

然而，研發和提供先進生物製藥的高昂成本構成了一大障礙，可能限制發展中地區取得這些藥物的機會。龐大的患者群體迫切需要擴充性且價格合理的解決方案。根據美國氣喘和過敏基金會預測，到2024年，美國將有超過1億人受到過敏性疾病的影響，這意味著市場對價格合理的治療方案有著巨大的需求。

市場促進因素

市場擴張的關鍵促進因素是全球過敏性和自體免疫疾病發生率的上升，這促使人們從暫時緩解症狀轉向永續的疾病管理。快速的都市化和飲食習慣的改變等因素正在增加全球人口的易感性，這不再局限於西方國家，而已成為全球性的健康挑戰。報導印證了這一擴張趨勢。該文章估計，目前全球約有8%的兒童和10%的成年人受到食物過敏的影響，促使醫療保健系統優先考慮準確診斷和長期照護。

同時，針對免疫異常根本原因的標靶治療，生物製藥和免疫療法的創新加速發展，正在改變這一領域。製藥公司正大力投資單株抗體和脫敏療法，例如，基因泰克公司在2024年2月宣布，其產品Zolia獲得美國FDA核准，成為首個用於減少多重食物過敏患者反應的藥物。這些進展的經濟潛力巨大，艾伯維公司報告稱，僅在2024年第三季度，其免疫學產品組合就創造了70.5億美元的全球收入淨額，凸顯了下一代解決方案的強勁市場潛力。

市場挑戰

研發和使用先進生物製藥所需的高昂成本是全球過敏和免疫市場成長的主要障礙。由於研發投入大規模，這些複雜的治療方法價格高昂，使得許多醫療系統和發展中國家的低收入患者難以負擔。這種經濟障礙阻礙了市場為日益成長的過敏患者群體提供充分的服務，導致相當一部分目標市場人群無法獲得這些有效的治療方法。

此外，過敏性疾病本身造成的經濟負擔也使得人們不願意採用更高成本的治療方法。根據美國氣喘和過敏基金會2024年的數據，氣喘每年對美國經濟造成的損失超過820億美元，凸顯了醫療基礎設施面臨的巨大壓力。因此，支付方往往不願意補貼昂貴的生物製藥療法，由此造成的經濟限制阻礙了這些先進免疫療法的廣泛應用。

市場趨勢

市場正經歷舌下免疫療法（SLIT）的顯著轉變。其非侵入性和居家使用的便利性使其成為傳統皮下注射療法的理想替代方案。這種方法無需頻繁就診，提高了患者的依從性，尤其適合需要長期減敏治療的上班族和兒童。製藥公司正積極響應這項需求，擴大其標準化過敏治療片劑的產品線。 ALK-Abello 在 2024 年年度報告中指出，截至 2025 年 2 月，其過敏免疫療法片劑的全球銷售額年增 24%，證實了口服製劑日益受到青睞。

此外，遠端醫療平台的整合正在革新醫療服務模式，透過虛擬諮詢和遠距症狀監測，實現慢性過敏症的管理。這一數位化趨勢有助於解決農村地區專科醫生短缺的問題，並支持混合護理模式，從而最佳化治療通訊協定，無需患者親自到診。美國國立衛生研究院 (NIH) 於 2025 年 11 月發布的報告《遠距過敏：遠端醫療在過敏症患者管理中的潛力》強調了人們對這些工具日益成長的依賴性。報告發現，在受訪的過敏症患者中，34% 的人曾使用遠端醫療服務來管理他們的症狀。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球過敏與免疫學市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依治療方法（皮下免疫療法（SCIT）、舌下免疫療法（SLIT）、片劑、滴鼻劑）
    • 依過敏類型（過敏性鼻炎、過敏性氣喘、其他過敏）
    • 按分銷管道（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美過敏和免疫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲過敏與免疫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區過敏與免疫市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東與非洲過敏與免疫市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲過敏和免疫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球過敏與免疫學市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc.
  • Stallergenes Greer PLC
  • Allergy Therapeutics
  • Sanofi SA
  • Anacor Pharmaceuticals Inc.
  • Novartis International AG
  • AstraZeneca
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • GlaxoSmithKline PLC
  • Mylan NV

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19829

The Global Allergy and Immunology Market is projected to expand from USD 2.81 Billion in 2025 to USD 3.96 Billion by 2031, registering a CAGR of 5.88%. This sector includes diagnostic tools, immunotherapies, and pharmaceutical interventions aimed at treating immune system disorders such as asthma, hypersensitivities, and autoimmune diseases. Growth is largely propelled by the increasing prevalence of allergic conditions worldwide, driven by urbanization and environmental pollution, as well as rising healthcare spending and broader awareness of immune health.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.81 Billion
Market Size 2031USD 3.96 Billion
CAGR 2026-20315.88%
Fastest Growing SegmentHospital Pharmacy
Largest MarketNorth America

However, the high costs involved in developing and delivering advanced biologic therapies present a significant obstacle, potentially limiting access in developing regions. The urgency for scalable and affordable solutions is highlighted by the sheer size of the patient population; according to the Asthma and Allergy Foundation of America, over 100 million people in the United States were affected by allergic conditions in 2024, demonstrating the vast scale of the market needing economical therapeutic options.

Market Driver

A primary catalyst for market expansion is the rising global incidence of allergic and autoimmune disorders, which is necessitating a transition from episodic symptom relief to sustained disease management. Factors such as rapid urbanization and shifting dietary habits have increased population sensitivity worldwide, making this a global health priority rather than just a Western issue. Highlighting this reach, an article in Frontiers in Nutrition from June 2024 titled 'Food allergies around the world' estimated that food allergies now impact approximately 8% of children and 10% of adults globally, prompting healthcare systems to prioritize accurate diagnostics and long-term care.

Simultaneously, the sector is being transformed by the acceleration of innovations in biologics and immunotherapies, which provide targeted treatments for the root causes of immune dysregulation. Pharmaceutical companies are heavily investing in monoclonal antibodies and desensitization therapies, evidenced by Genentech's February 2024 announcement that the U.S. FDA approved Xolair as the first medicine to reduce reactions in patients with multiple food allergies. The economic potential of these advancements is significant; AbbVie reported that its immunology portfolio generated $7.05 billion in global net revenues during the third quarter of 2024 alone, confirming the high market viability of next-generation solutions.

Market Challenge

The substantial expense required to develop and administer advanced biologic therapies stands as a major impediment to the growth of the Global Allergy and Immunology Market. The high pricing resulting from extensive research and development makes these complex treatments inaccessible for many healthcare systems in developing regions and patients with inadequate insurance. This financial barrier prevents the market from fully serving the expanding population of patients with allergic conditions, leaving a significant portion of the addressable market without access to these effective interventions.

Moreover, the existing economic burden of allergic diseases creates hesitation regarding the adoption of further high-cost treatments. Data from the Asthma and Allergy Foundation of America in 2024 indicated that the annual economic cost of asthma to the U.S. economy surpassed $82 billion, underscoring the strain on healthcare infrastructure. Consequently, payers are often reluctant to subsidize expensive biologic therapies, causing fiscal constraints that hinder the widespread expansion and adoption of these advanced immunological treatments.

Market Trends

The market is experiencing a notable shift toward Sublingual Immunotherapy (SLIT), which is becoming a preferred alternative to traditional subcutaneous injections due to its non-invasive nature and convenience for home use. This approach enhances patient compliance by removing the need for frequent clinic visits, making it highly suitable for working adults and children requiring long-term desensitization. Pharmaceutical firms are responding to this demand by increasing their offerings of standardized allergy tablets; ALK-Abello reported in its 'Annual Report 2024' that global sales of its allergy immunotherapy tablets rose by 24% in February 2025 compared to the prior year, confirming the growing preference for oral formulations.

In addition, the integration of telehealth platforms is revolutionizing care delivery by facilitating virtual consultations and remote symptom monitoring for chronic allergy management. This digital shift helps overcome specialist shortages in rural locations and supports hybrid care models that optimize treatment protocols without necessitating physical office visits. The growing reliance on these tools is evident in a November 2025 report by the National Institutes of Health, 'TeleAllergy: Potential of Telemedicine in Management of Patients With Allergies,' which noted that 34% of allergic patients surveyed had utilized telemedicine services to manage their conditions.

Key Market Players

  • AbbVie Inc.
  • Stallergenes Greer PLC
  • Allergy Therapeutics
  • Sanofi SA
  • Anacor Pharmaceuticals Inc.
  • Novartis International AG
  • AstraZeneca
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • GlaxoSmithKline PLC
  • Mylan N.V.

Report Scope

In this report, the Global Allergy And Immunology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy And Immunology Market, By Treatment Type

  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)
  • Tablets
  • Drops

Allergy And Immunology Market, By Allergy Type

  • Allergic Rhinitis
  • Allergic Asthma
  • Other Allergies

Allergy And Immunology Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Allergy And Immunology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy And Immunology Market.

Available Customizations:

Global Allergy And Immunology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy And Immunology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), Tablets, Drops)
    • 5.2.2. By Allergy Type (Allergic Rhinitis, Allergic Asthma, Other Allergies)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Allergy And Immunology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Allergy Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Allergy And Immunology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Allergy Type
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Allergy And Immunology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Allergy Type
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Allergy And Immunology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Allergy Type
        • 6.3.3.2.3. By Distribution Channel

7. Europe Allergy And Immunology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Allergy Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Allergy And Immunology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Allergy Type
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Allergy And Immunology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Allergy Type
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Allergy And Immunology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Allergy Type
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Allergy And Immunology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Allergy Type
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Allergy And Immunology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Allergy Type
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Allergy And Immunology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Allergy Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Allergy And Immunology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Allergy Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Allergy And Immunology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Allergy Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Allergy And Immunology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Allergy Type
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Allergy And Immunology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Allergy Type
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Allergy And Immunology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Allergy Type
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Allergy And Immunology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Allergy Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Allergy And Immunology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Allergy Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Allergy And Immunology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Allergy Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Allergy And Immunology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Allergy Type
        • 9.3.3.2.3. By Distribution Channel

10. South America Allergy And Immunology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Allergy Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Allergy And Immunology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Allergy Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Allergy And Immunology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Allergy Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Allergy And Immunology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Allergy Type
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Allergy And Immunology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Stallergenes Greer PLC
  • 15.3. Allergy Therapeutics
  • 15.4. Sanofi SA
  • 15.5. Anacor Pharmaceuticals Inc.
  • 15.6. Novartis International AG
  • 15.7. AstraZeneca
  • 15.8. Merck KGaA
  • 15.9. F. Hoffmann-La Roche Ltd
  • 15.10. Johnson & Johnson
  • 15.11. GlaxoSmithKline PLC
  • 15.12. Mylan N.V.

16. Strategic Recommendations

17. About Us & Disclaimer